

Appendix Table F74. Discontinuation due to adverse effects after pharmacological treatments for UI when compared to each other

| Reference | Active drug | Dose | Control Drug | Dose | Active n/N | Control n/N | Relative risk (95% CI) | Absolute risk difference (95% CI) |
|--------------------------------|----------------|------------------|----------------|------------------|------------|-------------|------------------------|-----------------------------------|
| Zinner, 2005 ⁴⁰⁵ | Darifenacin ER | 15mg/day | Oxybutynin | 5 mg 3 times/day | 0/19 | 4/19 | 0.1(0.0; 1.9) | -0.21 (-0.41; -0.02) |
| Appell, 1997 ²²² | Oxybutynin | 5mg/day | Tolterodine | 1mg/day | 70/349 | 2/121 | 12.1(3.0; 48.7) | 0.18 (0.14; 0.23) |
| Abrams, 1998 ²¹⁹ | Tolterodine | 2mg twice daily | Oxybutynin | 5mg thrice daily | 20/118 | 10/118 | 2.0(1.0; 4.1) | 0.08 (0.00; 0.17) |
| Drutz, 1999 ²⁷⁹ | Oxybutynin | 5mg thrice a day | Tolterodine | 2mg twice a day | 23/112 | 7/109 | 3.2(1.4; 7.1) | 0.14 (0.05; 0.23) |
| Appell, 2001 ²²³ | Oxybutynin | 10mg/day | Tolterodine LA | 2mg twice daily | 14/185 | 15/193 | 1.0(0.5; 2.0) | 0.00 (-0.06; 0.05) |
| Lee, 2002 ³³² | Oxybutynin | 5mg twice daily | Tolterodine | 2mg twice daily | 18/116 | 11/112 | 1.6(0.8; 3.2) | 0.06 (-0.03; 0.14) |
| Halaska, 2003 ²⁹⁸ | Tropium | 20mg twice daily | Oxybutynin | 5mg twice daily | 10/267 | 6/90 | 0.6(0.2; 1.5) | -0.03 (-0.09; 0.03) |
| Diokno, 2003 ²²⁷ | Oxybutynin | 10mg/d | Tolterodine ER | 4mg/d | 20/391 | 19/399 | 1.1(0.6; 2.0) | 0.00 (-0.03; 0.03) |
| Chapple, 2004 ⁵² | Solifenacin | 5mg daily | Tolterodine | 2mg twice daily | 9/279 | 5/266 | 1.7(0.6; 5.1) | 0.01 (-0.01; 0.04) |
| Chapple, 2004 ⁵² | Solifenacin | 10mg daily | Tolterodine | 2mg twice daily | 7/269 | 5/266 | 1.4(0.4; 4.3) | 0.01 (-0.02; 0.03) |
| Homma, 2004 ³⁰⁶ | Oxybutynin | 3mg thrice daily | Tolterodine ER | 4mg/day | 21/122 | 6/114 | 3.3(1.4; 7.8) | 0.12 (0.04; 0.20) |
| Sand, 2004 ²²⁶ | Oxybutynin | 10mg/day | Tolterodine | 2mg b.i.d. | 11/152 | 12/163 | 1.0(0.4; 2.2) | 0.00 (-0.06; 0.06) |
| Chapple, 2005 ²⁵² | Darifenacin ER | 15mg daily | Oxybutynin IR | 5mg t.i.d. | 1/12 | 0/12 | 3.0(0.1; 67.1) | 0.08 (-0.12; 0.29) |
| Chapple, 2005 ²⁵² | Darifenacin ER | 30mg daily | Oxybutynin IR | 5mg t.i.d. | 1/13 | 2/12 | 0.5(0.0; 4.5) | -0.09 (-0.35; 0.17) |
| Chapple, 2005 ²⁵² | Darifenacin IR | 2.5mg t.i.d. | Oxybutynin IR | 2.5 t.i.d. | 0/8 | 1/8 | 0.3(0.0; 7.1) | -0.13 (-0.41; 0.16) |
| Zinner, 2005 ⁴⁰⁵ | Darifenacin ER | 30mg/day | Oxybutynin | 5 mg 3 times/day | 1/19 | 4/19 | 0.3(0.0; 2.0) | -0.16 (-0.37; 0.05) |
| Armstrong, 2005 ²²⁴ | Oxybutynin | 10mg/day | Tolterodine ER | 4mg daily | 20/391 | 19/399 | 1.1(0.6; 2.0) | 0.00 (-0.03; 0.03) |
| Armstrong, 2007 ²²⁵ | Oxybutynin | 10mg qd | Tolterodine ER | 2mg qd | 155/576 | 61/193 | 0.9(0.7; 1.1) | -0.05 (-0.12; 0.03) |
| Armstrong, 2007 ²²⁵ | Oxybutynin | 10mg qd | Tolterodine IR | 2mg bid | 35/576 | 15/193 | 0.8(0.4; 1.4) | -0.02 (-0.06; 0.03) |
| Chapple, 2007 ²⁵⁸ | Solifenacin | 5mg daily | Tolterodine | 4mg daily | 4/578 | 7/599 | 0.6(0.2; 2.0) | 0.00 (-0.02; 0.01) |
| Chapple, 2007 ²⁵³ | Tolterodine | 4mg daily | Fesoterodine | 8mg daily | 14/288 | 9/290 | 1.6(0.7; 3.6) | 0.02 (-0.01; 0.05) |
| Chapple, 2007 ²⁵³ | Tolterodine | 4mg daily | Fesoterodine | 4mg daily | 7/272 | 9/290 | 0.8(0.3; 2.2) | -0.01 (-0.03; 0.02) |

Appendix Table F74. Discontinuation due to adverse effects after pharmacological treatments for UI when compared to each other (continued)

| Reference | Active drug | Dose | Control Drug | Dose | Active n/N | Control n/N | Relative risk (95% CI) | Absolute risk difference (95% CI) |
|--|----------------|--------------------------------|----------------|---------------------------|------------|-------------|------------------------|-----------------------------------|
| Yamaguchi, 2007 ⁴⁰³ | Solifenacin | 5mg daily | Propiverine | 20mg daily | 20/400 | 26/402 | 0.8(0.4; 1.4) | -0.01 (-0.05; 0.02) |
| Yamaguchi, 2007 ⁴⁰³ | Solifenacin | 10mg daily | Propiverine | 20mg daily | 26/385 | 26/402 | 1.0(0.6; 1.8) | 0.00 (-0.03; 0.04) |
| Choo, 2008 ²⁶³ | Solifenacin | 5mg once daily | Tolterodine IR | 2mg twice daily | 5/120 | 2/118 | 2.5(0.5; 12.4) | 0.02 (-0.02; 0.07) |
| Choo, 2008 ²⁶³ | Solifenacin | 10mg once daily | Tolterodine IR | 2mg twice daily | 7/119 | 2/118 | 3.5(0.7; 16.4) | 0.04 (-0.01; 0.09) |
| Zellner, 2009 ⁴⁰⁴ | Trospium | 15mg to 30mg thrice daily | Oxybutynin | 2.5mg to 5mg thrice daily | 47/828 | 61/830 | 1.3(0.9; 1.9) | -0.017 (-0.04; 0.007) |
| Herschorn, 2010 ⁴⁷⁰ | Tolterodine ER | 4mg once daily | Fesoterodine | 4-8mg once daily | 44/679 | 28/684 | 1.6(1.0; 2.5) | 0.02 (0.00; 0.05) |
| Herschorn, 2010 ³⁰⁰ | Solifenacin | 5mg once daily | Oxybutynin IR | 5mg 3 times daily | 7/68 | 7/64 | 0.9(0.3; 2.5) | -0.01 (-0.11; 0.10) |
| U.S. Food and Drug Administration ²⁵⁷ | Solifenacin | 5mg once daily/5mg twice daily | Tolterodine ER | 4mg once daily | 25/593 | 23/607 | 1.1(0.6; 1.9) | 0.00 (-0.02; 0.03) |
| Kaplan, 2010 ³¹⁸ | Fesoterodine | 4 to 8mg once daily | Tolterodine ER | 4 mg once daily | 48/963 | 29/974 | 1.7(1.1; 2.6) | 0.02 (0.00; 0.04) |
| But, 2010 ²⁴³ | Solifenacin | Not reported | Darifenacin | Not reported | 8/40 | 8/37 | 0.9(0.4; 2.2) | -0.02 (-0.20; 0.17) |
| NCT00444925 ⁵⁶ | Fesoterodine | 4 to 8mg once daily | Tolterodine ER | 4 to 8mg once daily | 44/685 | 28/690 | 1.6(1.0; 2.5) | 0.02 (0.00; 0.05) |